Compare Immunovia AB with Similar Stocks
Stock DNA
Pharmaceuticals & Biotechnology
SEK 109 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
-1.18
-225.40%
1.68
Revenue and Profits:
Net Sales:
0 Million
(Quarterly Results - Dec 2025)
Net Profit:
-17 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-27.07%
0%
-27.07%
6 Months
-54.69%
0%
-54.69%
1 Year
-27.2%
0%
-27.2%
2 Years
-67.29%
0%
-67.29%
3 Years
-93.55%
0%
-93.55%
4 Years
-98.71%
0%
-98.71%
5 Years
-99.62%
0%
-99.62%
Immunovia AB for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
5.71%
EBIT Growth (5y)
7.11%
EBIT to Interest (avg)
-57.29
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.28
Sales to Capital Employed (avg)
0.03
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
11.90
EV to EBIT
-1.89
EV to EBITDA
-2.11
EV to Capital Employed
-16.49
EV to Sales
182.40
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-827.60%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
Bearish
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Mildly Bullish
Dow Theory
Bearish
Bearish
OBV
No Trend
Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ
Dec'25
Sep'25
Change(%)
Net Sales
0.40
0.10
300.00%
Operating Profit (PBDIT) excl Other Income
-15.60
-24.60
36.59%
Interest
1.40
4.70
-70.21%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-17.30
-29.70
41.75%
Operating Profit Margin (Excl OI)
-45,997.20%
-248,029.70%
20,203.25%
USD in Million.
Net Sales
QoQ Growth in quarter ended Dec 2025 is 300.00% vs 0.00% in Sep 2025
Consolidated Net Profit
QoQ Growth in quarter ended Dec 2025 is 41.75% vs 27.74% in Sep 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
0.70
0.90
-22.22%
Operating Profit (PBDIT) excl Other Income
-77.20
-93.50
17.43%
Interest
66.10
1.90
3,378.95%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-145.90
-76.50
-90.72%
Operating Profit Margin (Excl OI)
-116,064.20%
-114,887.20%
-117.70%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is -22.22% vs -43.75% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is -90.72% vs 75.27% in Dec 2024
About Immunovia AB 
Immunovia AB
Pharmaceuticals & Biotechnology
Immunovia AB (publ) is a Sweden-based diagnostic company that is developing and commercializing blood tests for the early detection of cancer and autoimmune diseases based on Immunovia’s test platform called IMMray. Tests are based on antibody biomarker microarray analysis using machine-learning and bioinformatics to single-out a set of relevant biomarkers that indicate a certain disease. Thus, forming a disease biomarker signature. Immunovia Dx Laboratories locations in USA and Sweden provides laboratory testing services in two accredited reference laboratories.
Company Coordinates 
Company Details
Medicon Village, Scheelevagen 2 , LUND None : 223 81
Registrar Details






